Categories: NeurologyNews

electroCore to Announce Third Quarter 2022 Financial Results on November 3

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

ROCKAWAY, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the third quarter ended September 30, 2022, after the close of the market on Thursday, November 3, 2022. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions.

Thursday, November 3, 2022, 4:30 PM EDT
Domestic: 877-269-7756
International: 201-689-7817
Conference ID: 13733010
Webcast: electroCore Earnings Webcast

About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its non-invasive vagus nerve stimulation therapy platform, initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventive treatment of cluster headache and migraine, the acute treatment of migraine and episodic cluster headache, the acute and preventive treatment of migraines in adolescents, and paroxysmal hemicrania and hemicrania continua in adults.

For more information, visit www.electrocore.com.

Contact:
Rich Cockrell
CG Capital
404-736-3838
ecor@cg.capital

Staff

Recent Posts

PreveCeutical Announces Update to Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - April 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB:…

4 hours ago

Lam Research Corporation Announces March Quarter Financial Conference Call

FREMONT, Calif., April 2, 2025 /PRNewswire/ -- Lam Research Corp. (NASDAQ: LRCX) today announced that…

6 hours ago

Former Pfizer R&D Chief Mikael Dolsten Joins Formation Bio to Chair Drug Picking Committee and Co-Chair its Investment Advisory Committee

NEW YORK, April 2, 2025 /PRNewswire/ -- Formation Bio, an AI-driven pharmaceutical company revolutionizing drug development,…

6 hours ago

Siemens acquires Dotmatics to extend AI-powered software portfolio to Life Sciences

Acquisition of Dotmatics, a leader in Life Sciences R&D software for $5.1 billionExpands Siemens' market-leading…

6 hours ago

PerZeption Appoints CTO to Enhance Visual Function Assessments

BOSTON, April 2, 2025 /PRNewswire/ -- PerZeption Inc., a U.S. vision diagnostics startup dedicated to…

6 hours ago

Dotmatics Signs Definitive Agreement to be Acquired by Siemens Advancing a New Era of AI-Driven Innovation in Life Sciences

Siemens AG will acquire Dotmatics from global software investor Insight Partners for $5.1 billionAcquisition accelerates…

6 hours ago